ArticleJournal of biochemical and molecular toxicology2026
A tsRNA Suppresses Lung Adenocarcinoma Progression Through Targeting Glucose-6-Phosphate Dehydrogenase.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A tsRNA Suppresses Lung Adenocarcinoma Progression Through Targeting Glucose-6-Phosphate Dehydrogenase.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elucidating the molecular distinctions between invasive and non-invasive forms of lung adenocarcinoma is essential for the development of personalized therapeutic approaches and the optimization of patient outcomes. Transfer RNA-derived small RNAs (tsRNAs) have been recognized as pivotal regulators in oncogenic processes. In this study, we identified a specific tsRNA associated with non-invasive lung adenocarcinoma and demonstrated its suppressive effects on cellular proliferation and metastatic potential. At the molecular level, this tsRNA exerts its regulatory function by targeting and repressing G6PD mRNA, thereby perturbing the equilibrium between NADPH and reactive oxygen species (ROS) production. This discovery positions the identified tsRNA as a promising candidate for therapeutic intervention in non-invasive lung adenocarcinoma. Further investigation into the role of tsRNAs in lung adenocarcinoma is imperative to fully harness their potential in clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.